The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.
Source: FDA.Gov – May 26, 2016
See Related Article
Can a Pricey Implant to Treat Opioid Addiction Save Lives – and Money? available at: https://www.statnews.com/2016/05/25/can-pricey-implant-treat-opioid-addiction-save-lives-money/